AstraZeneca Acquires Amolyt Pharma for $1.05 Billion

The deal aims to bolster AstraZeneca's portfolio in rare disease treatments, with a focus on hypoparathyroidism.

AstraZeneca is set to acquire Amolyt Pharma for $1.05 billion, aiming to enhance its rare disease treatment portfolio, specifically targeting hypoparathyroidism.
The acquisition deal includes an $800 million upfront payment and an additional $250 million contingent on regulatory milestones.
Amolyt Pharma's lead drug, in late-stage development for hypoparathyroidism, could benefit approximately 222,000 people in the US and EU, with a significant majority being women.
AstraZeneca's rare disease arm, Alexion, will spearhead the development and global commercialization of Amolyt Pharma's pipeline.
The deal is expected to close by the end of the third quarter of 2024, marking another significant acquisition by AstraZeneca in its expansion efforts.